1. Pink Sheet

With J&J’s COVID Vaccine Pause Now Lifted, The Question Is How Well The System Worked

 
• By Brenda Sandburg

Number of deaths and ICU admissions that may have been prevented without the pause is ‘striking,’ CDC advisory committee member says; ACIP votes to reaffirm use of J&J’s vaccine in persons 18 and older based on positive risk-benefit analysis and reports of only nine additional cases of TTS.

The new warning is set, but still unresolved is how the pause will reflect on the J&J vaccine and FDA in the long term. • Source: photo illustration

Additional analysis of the pros and cons of Johnson & Johnson’s COVID-19 vaccine, along with only a few new cases of rare blood clots, persuaded the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) to vote to lift the pause on its administration, a step it was not ready to take a week earlier.

With the extended stoppage now over, the question for sponsors and public health officials is what impact it will have on the effort to eradicate the pandemic through vaccination and whether

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet